Cardiol Therapeutics Inc. is a clinical stage life sciences company advancing late stage anti inflammatory and anti fibrotic therapies for heart disease. Its lead small molecule drug candidate CardiolRx modulates the inflammasome pathway which plays a role in inflammation and fibrosis associated with pericarditis myocarditis and heart failure. The MAVERIC Program evaluates CardiolRx for the treatment of recurrent pericarditis an inflammatory disease of the pericardium that causes chest pain shortness of breath fatigue and can lead to hospitalizations. The program includes the completed Phase II MAvERIC Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis including recurrent pericarditis. The ARCHER Program has studied CardiolRx in acute myocarditis a condition that can cause acute fulminant heart failure in young adults and is a leading cause of sudden cardiac death in individuals under 35 years of age. The ARCHER program consists of the completed Phase II ARCHER study (NCT05180240) which evaluated the safety tolerability and efficacy of CardiolRx in this patient population. In addition the company is developing CRD 38 a novel subcutaneously administered formulation intended for inflammatory heart disease including heart failure a condition that generates over US$30 billion in annual healthcare costs in the United States.

Cardiol Therapeutics Inc. does not currently generate product revenue because it has no approved therapies on the market. The company states that it does not expect to receive product revenue for several years if at all from its drug candidates. Historical financial statements show operating losses and the company expects to continue incurring losses as it advances its clinical programs. Funding is obtained primarily through equity financings and occasional payments from collaborative partners. No milestone payments or royalty income have been reported to date.

Cardiol Therapeutics Inc. occupies an early stage position in the cardiovascular therapy landscape with a focus on modulating inflammation and fibrosis pathways. The lead candidate CardiolRx has received Orphan Drug Designation from the US FDA for pericarditis including recurrent pericarditis which may confer market exclusivity upon approval. Clinical data from the Phase II MAvERIC Pilot study and the Phase II ARCHER study provide initial evidence of safety and biological activity in the targeted patient groups. The mechanism of action targeting the inflammasome complex differentiates CardiolRx from many existing heart failure therapies that act through other pathways. By pursuing subcutaneous delivery with CRD 38 the company aims to improve patient adherence and expand the potential addressable population. While the field of anti inflammatory cardiac therapies includes several competitors the company’s novel mechanism and formulation approach provide a distinct competitive edge.

Cardiol Therapeutics Inc. collaborates with a network of clinical trial sites academic medical centers and research organizations to enroll patients in its studies. Named collaborators referenced in the filing include TecSalud the University of Virginia Houston Methodist DeBakey Heart and Vascular Center and Massachusetts General Hospital. The company also engages contract research organizations and contract manufacturing organizations to support drug development and production. Specific service providers mentioned are Dalton Pharma Services and Purisys which assist with manufacturing and analytical tasks. These relationships supply the necessary expertise infrastructure and regulatory support for conducting clinical trials and preparing submissions.